164 related articles for article (PubMed ID: 30105842)
1. Costimulatory checkpoint SLAMF8 is an independent prognosis factor in glioma.
Zou CY; Guan GF; Zhu C; Liu TQ; Guo Q; Cheng W; Wu AH
CNS Neurosci Ther; 2019 Mar; 25(3):333-342. PubMed ID: 30105842
[TBL] [Abstract][Full Text] [Related]
2. SLAMF8 can predict prognosis of pan-cancer and the immunotherapy response effectivity of gastric cancer.
Li G; Li Q; Ping M; Jiao Z; Wang X; Cheng J; Guo J; Cheng Y
Aging (Albany NY); 2024 May; 16(10):8944-8964. PubMed ID: 38787377
[TBL] [Abstract][Full Text] [Related]
3. CD48 is a key molecule of immunomodulation affecting prognosis in glioma.
Zou C; Zhu C; Guan G; Guo Q; Liu T; Shen S; Yan Z; Xu X; Lin Z; Chen L; Wu A; Cheng W
Onco Targets Ther; 2019; 12():4181-4193. PubMed ID: 31213836
[No Abstract] [Full Text] [Related]
4. SLAMF8, a potential new immune checkpoint molecule, is associated with the prognosis of colorectal cancer.
Zhang Y; Zhang Q; Han X; Han L; Wang T; Hu J; Li L; Ding Z; Shi X; Qian X
Transl Oncol; 2023 May; 31():101654. PubMed ID: 36931016
[TBL] [Abstract][Full Text] [Related]
5. SLAM family member 8 is involved in oncogenic KIT-mediated signalling in human mastocytosis.
Sugimoto A; Kataoka TR; Ueshima C; Takei Y; Kitamura K; Hirata M; Nomura T; Haga H
Exp Dermatol; 2018 Jun; 27(6):641-646. PubMed ID: 29498772
[TBL] [Abstract][Full Text] [Related]
6. NR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human glioma.
Miftah H; Naji O; Ssi SA; Ghouzlani A; Lakhdar A; Badou A
Front Immunol; 2023; 14():1139268. PubMed ID: 37575237
[TBL] [Abstract][Full Text] [Related]
7. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
Chen J; Hou C; Wang P; Yang Y; Zhou D
World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
[TBL] [Abstract][Full Text] [Related]
8. Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker FAM111A in Diffuse Lower-Grade Glioma.
Ji X; Ding F; Gao J; Huang X; Liu W; Wang Y; Liu Q; Xin T
Front Oncol; 2020; 10():573800. PubMed ID: 33194678
[TBL] [Abstract][Full Text] [Related]
9. FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients.
Wang Z; Zhang C; Sun L; Liang J; Liu X; Li G; Yao K; Zhang W; Jiang T
Oncotarget; 2016 Dec; 7(51):84587-84593. PubMed ID: 27829236
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes.
Qi Y; Liu B; Sun Q; Xiong X; Chen Q
Front Immunol; 2020; 11():578877. PubMed ID: 33329549
[TBL] [Abstract][Full Text] [Related]
11. IFI30 Is a Novel Immune-Related Target with Predicting Value of Prognosis and Treatment Response in Glioblastoma.
Zhu C; Chen X; Guan G; Zou C; Guo Q; Cheng P; Cheng W; Wu A
Onco Targets Ther; 2020; 13():1129-1143. PubMed ID: 32103982
[TBL] [Abstract][Full Text] [Related]
12. TMIGD2 as a potential therapeutic target in glioma patients.
Boulhen C; Ait Ssi S; Benthami H; Razzouki I; Lakhdar A; Karkouri M; Badou A
Front Immunol; 2023; 14():1173518. PubMed ID: 37261362
[TBL] [Abstract][Full Text] [Related]
13. SLAM family member 8 is expressed in and enhances the growth of anaplastic large cell lymphoma.
Sugimoto A; Kataoka TR; Ito H; Kitamura K; Saito N; Hirata M; Ueshima C; Takei Y; Moriyoshi K; Otsuka Y; Nishikori M; Takaori-Kondo A; Haga H
Sci Rep; 2020 Feb; 10(1):2505. PubMed ID: 32054954
[TBL] [Abstract][Full Text] [Related]
14. DNA Damage Response Evaluation Provides Novel Insights for Personalized Immunotherapy in Glioma.
Chen M; Huang B; Zhu L; Wang Q; Pang Y; Cheng M; Lian H; Liu M; Zhao K; Xu S; Zhang J; Zhong C
Front Immunol; 2022; 13():875648. PubMed ID: 35720326
[TBL] [Abstract][Full Text] [Related]
15. Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
Wang PF; Cai HQ; Zhang CB; Li YM; Liu X; Wan JH; Jiang T; Li SW; Yan CX
J Neuroinflammation; 2018 May; 15(1):145. PubMed ID: 29764444
[TBL] [Abstract][Full Text] [Related]
16. SLAMF8 Downregulates Mouse Macrophage Microbicidal Mechanisms
Romero-Pinedo S; Barros DIR; Ruiz-Magaña MJ; Maganto-García E; Moreno de Lara L; Abadía-Molina F; Terhorst C; Abadía-Molina AC
Front Immunol; 2022; 13():910112. PubMed ID: 35837407
[TBL] [Abstract][Full Text] [Related]
17. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
18. Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas.
Guan X; Luo L; Begum G; Kohanbash G; Song Q; Rao A; Amankulor N; Sun B; Sun D; Jia W
J Exp Clin Cancer Res; 2018 Oct; 37(1):255. PubMed ID: 30333031
[TBL] [Abstract][Full Text] [Related]
19. Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.
Li G; Wang Z; Zhang C; Liu X; Cai J; Wang Z; Hu H; Wu F; Bao Z; Liu Y; Zhao L; Liang T; Yang F; Huang R; Zhang W; Jiang T
Oncoimmunology; 2017; 6(8):e1328339. PubMed ID: 28919992
[No Abstract] [Full Text] [Related]
20. Lighting a Fire: Gasdermin-Mediated Pyroptosis Remodels the Glioma Microenvironment and Promotes Immune Checkpoint Blockade Response.
Cai Y; Li K; Lin J; Liang X; Xu W; Zhan Z; Xue S; Zeng Y; Chai P; Mao Y; Song Z; Han L; Song Y; Zhang X; Wang H
Front Immunol; 2022; 13():910490. PubMed ID: 35784306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
